Revvity Revenue 2012-2026 | RVTY
Revvity annual/quarterly revenue history and growth rate from 2012 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Revvity revenue for the quarter ending March 31, 2026 was $0.711B, a 6.97% increase year-over-year.
- Revvity revenue for the twelve months ending March 31, 2026 was $2.902B, a 4.79% increase year-over-year.
- Revvity annual revenue for 2025 was $2.856B, a 3.67% increase from 2024.
- Revvity annual revenue for 2024 was $2.755B, a 0.16% increase from 2023.
- Revvity annual revenue for 2023 was $2.751B, a 16.95% decline from 2022.
|
Revvity Annual Revenue (Millions of US $) |
|
|---|---|
| 2025 | $2,856 |
| 2024 | $2,755 |
| 2023 | $2,751 |
| 2022 | $3,312 |
| 2021 | $3,828 |
| 2020 | $2,663 |
| 2019 | $2,884 |
| 2018 | $2,778 |
| 2017 | $2,257 |
| 2016 | $2,116 |
| 2015 | $2,105 |
| 2014 | $2,070 |
| 2013 | $2,158 |
| 2012 | $2,105 |
| 2011 | $1,919 |
|
Revvity Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2026-03-31 | $711 |
| 2025-12-31 | $772 |
| 2025-09-30 | $699 |
| 2025-06-30 | $720 |
| 2025-03-31 | $665 |
| 2024-12-31 | $729 |
| 2024-09-30 | $684 |
| 2024-06-30 | $692 |
| 2024-03-31 | $650 |
| 2023-12-31 | $696 |
| 2023-09-30 | $671 |
| 2023-06-30 | $709 |
| 2023-03-31 | $675 |
| 2022-12-31 | $741 |
| 2022-09-30 | $712 |
| 2022-06-30 | $896 |
| 2022-03-31 | $963 |
| 2021-12-31 | $430 |
| 2021-09-30 | $861 |
| 2021-06-30 | $1,228 |
| 2021-03-31 | $1,308 |
| 2020-12-31 | $235 |
| 2020-09-30 | $964 |
| 2020-06-30 | $812 |
| 2020-03-31 | $652 |
| 2019-12-31 | $805 |
| 2019-09-30 | $707 |
| 2019-06-30 | $723 |
| 2019-03-31 | $649 |
| 2018-12-31 | $756 |
| 2018-09-30 | $674 |
| 2018-06-30 | $703 |
| 2018-03-31 | $644 |
| 2017-12-31 | $642 |
| 2017-09-30 | $554 |
| 2017-06-30 | $547 |
| 2017-03-31 | $514 |
| 2016-12-31 | $567 |
| 2016-09-30 | $514 |
| 2016-06-30 | $536 |
| 2016-03-31 | $498 |
| 2015-12-31 | $451 |
| 2015-09-30 | $563 |
| 2015-06-30 | $564 |
| 2015-03-31 | $527 |
| 2014-12-31 | $441 |
| 2014-09-30 | $542 |
| 2014-06-30 | $556 |
| 2014-03-31 | $531 |
| 2013-12-31 | $589 |
| 2013-09-30 | $522 |
| 2013-06-30 | $541 |
| 2013-03-31 | $505 |
| 2012-12-31 | $563 |
| 2012-09-30 | $510 |
| 2012-06-30 | $522 |
| 2012-03-31 | $511 |
| 2011-12-31 | $539 |
| 2011-09-30 | $453 |
| 2011-06-30 | $479 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.039B | $2.856B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $134.187B | 24.31 |
| HCA Healthcare (HCA) | United States | $110.772B | 17.53 |
| CVS Health (CVS) | United States | $101.670B | 11.75 |
| Elevance Health (ELV) | United States | $68.432B | 10.33 |
| Cencora (COR) | United States | $62.409B | 19.63 |
| Natera (NTRA) | United States | $27.358B | 0.00 |
| Labcorp Holdings (LH) | United States | $21.501B | 15.87 |
| DiDi Global (DIDIY) | China | $18.026B | 15.96 |
| Viatris (VTRS) | United States | $15.685B | 5.71 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $14.535B | 0.00 |
| Medpace Holdings (MEDP) | United States | $14.094B | 32.26 |
| BioMerieux (BMXMF) | France | $12.476B | 0.00 |
| Solventum (SOLV) | United States | $11.408B | 10.78 |
| BrightSpring Health Services (BTSG) | United States | $8.774B | 43.59 |
| Charles River Laboratories (CRL) | United States | $8.667B | 17.09 |
| ICON (ICLR) | Ireland | $8.626B | 8.56 |
| CochLear (CHEOY) | Australia | $8.030B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $6.905B | 0.00 |
| HealthEquity (HQY) | United States | $6.586B | 23.20 |
| Bausch + Lomb (BLCO) | Canada | $5.877B | 32.98 |
| GETINGE (GNGBY) | Sweden | $5.626B | 17.96 |
| Avantor (AVTR) | United States | $5.388B | 8.68 |
| PACS (PACS) | United States | $5.304B | 27.44 |
| Caris Life Sciences,�Inc (CAI) | United States | $5.101B | 0.00 |
| Sotera Health (SHC) | United States | $4.380B | 19.95 |
| Alignment Healthcare (ALHC) | United States | $4.188B | 0.00 |
| Concentras Parent (CON) | United States | $2.818B | 16.12 |
| Organon (OGN) | United States | $2.299B | 2.57 |
| Amplifon S.p.A (AMFPF) | Italy | $2.275B | 13.27 |
| Pediatrix Medical (MD) | United States | $1.782B | 11.11 |
| Establishment Labs Holdings (ESTA) | United States | $1.765B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.746B | 42.28 |
| Surgery Partners (SGRY) | United States | $1.671B | 41.65 |
| Sonida Senior Living (SNDA) | United States | $1.544B | 0.00 |
| Ardent Health (ARDT) | United States | $1.345B | 5.70 |
| Progyny (PGNY) | United States | $1.277B | 25.08 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.240B | 0.00 |
| InnovAge Holding (INNV) | United States | $1.113B | 164.00 |
| Teladoc Health (TDOC) | United States | $0.920B | 0.00 |
| CareDx (CDNA) | United States | $0.822B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $0.750B | 12.17 |
| Enhabit (EHAB) | United States | $0.709B | 25.89 |
| Nutex Health (NUTX) | United States | $0.704B | 11.25 |
| Omada Health (OMDA) | United States | $0.672B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.604B | 99.85 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.531B | 0.00 |
| Embecta (EMBC) | United States | $0.524B | 2.92 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.497B | 0.00 |
| CryoPort (CYRX) | United States | $0.482B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.435B | 4.70 |
| SBC Medicals (SBC) | United States | $0.426B | 8.47 |
| Forward Industries (FWDI) | United States | $0.375B | 0.00 |
| Strata Critical Medical (SRTA) | United States | $0.349B | 0.00 |
| Agilon Health (AGL) | United States | $0.316B | 0.00 |
| Shoulder Innovations (SI) | United States | $0.309B | 0.00 |
| Oncology Institute (TOI) | United States | $0.304B | 0.00 |
| So-Young (SY) | China | $0.262B | 0.00 |
| LifeMD (LFMD) | United States | $0.166B | 0.00 |
| Biodesix (BDSX) | United States | $0.133B | 0.00 |
| Beauty Health (SKIN) | United States | $0.115B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.091B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.080B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.077B | 0.00 |
| DocGo (DCGO) | United States | $0.051B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.037B | 0.00 |
| Pomdoctor - (POM) | China | $0.031B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.026B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.018B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.015B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.011B | 0.00 |
| Lifeward (LFWD) | United States | $0.010B | 0.00 |
| XWELL (XWEL) | United States | $0.009B | 0.00 |
| Aclarion (ACON) | United States | $0.007B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.007B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| Co-Diagnostics (CODX) | United States | $0.005B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |